Jaguar health shares replay link for march 14, 2022, investor webcast

Click here to access webcast replay core 2022 development initiatives: ongoing operation of company's ontarget phase 3 clinical trial of crofelemer for prophylaxis of cancer therapy-related diarrhea (ctd) initiation and completion in 2h 2022 of investigator-initiated proof-of-concept study of crofelemer for short bowel syndrome with intestinal failure (sbs-if) fda conditional approval in december 2021 of canalevia™-ca1 for treatment of chemotherapy-induced diarrhea (cid) in dogs fourth quarter 2021 mytesi net revenue was approximately $2.1 million versus approximately $0.6 million in the third quarter of 2021, an increase of 230% san francisco, ca / accesswire / march 14, 2022 / jaguar health, inc. (nasdaq:jagx) today announced that the recording of the company's march 14, 2022, investor webcast regarding company updates and reported consolidated financial results for the year ended december 31, 2021 can be accessed by clicking here . about jaguar health, jaguar animal health, napo pharmaceuticals, & napo therapeutics jaguar health, inc. is a commercial stage pharmaceuticals company focused on developing novel, plant-based, non-opioid, and sustainably derived prescription medicines for people and animals with gi distress, including chronic, debilitating diarrhea.
JAGX Ratings Summary
JAGX Quant Ranking